Sovateltide clinical trials
Sovateltide is named as an intervention in 3 current clinical trials in our India, UK, USA, Germany and Spain registers. 2 are recruiting patients now. The most common phase is Phase 3. The lead sponsor is Pharmazz, Inc. The most-studied condition is Acute Ischemic Stroke.
How Sovateltide works
All drug targets →- Ischemic strokePhase 3
- Alzheimer diseasePhase 2
- Biliary tract neoplasmPhase 2
- Brain ischemiaPhase 2
- Neonatal encephalopathyPhase 2
- Non-small cell lung carcinomaPhase 2
- Spinal cord injuryPhase 2
- CarcinomaPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL3188091, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 1007, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Sovateltide
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Sovateltide
- ChEMBL
- CHEMBL3188091
- DrugBank
- DB06138
- PubChem CID
- 56947141
- CAS number
- 142569-99-1
- Wikidata
- Q27078111
- Wikipedia
- Sovateltide
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Sovateltide
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05691244 · Acute Ischemic Stroke, Cerebral Stroke
|
Phase 3 | Recruiting | Pharmazz, Inc | UK, USA, Germany, Spain |
|
Assess Safety and Efficacy of Sovateltide in Hypoxic-ischemic Encephalopathy
NCT05514340 · Hypoxic-Ischemic Encephalopathy, Neonatal Asphyxia, Neonatal Encephalopathy
|
Phase 2 | Recruiting | Pharmazz, Inc | India |
|
Study to Assess the Safety and Efficacy of Sovateltide in Patients With Acute Cerebral Ischemic Stroke
NCT05955326 · Acute Cerebral Ischemia
|
Phase 4 | Active, closed | Pharmazz, Inc | India |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Sovateltide
6 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Pharmazz, Inc | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in India | 2 | 1 |
| Clinical trials in UK | 1 | 1 |
| Clinical trials in USA | 1 | 1 |
| Clinical trials in Germany | 1 | 1 |
| Clinical trials in Spain | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Sovateltide trials
How many clinical trials are testing Sovateltide?
3 current trials in our India, UK, USA, Germany and Spain registers name Sovateltide (also registered as PMZ-1620) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Sovateltide trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 1 with sites in India, 1 with sites in UK, 1 with sites in USA, 1 with sites in Germany and 1 with sites in Spain. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Sovateltide clinical trials?
The lead sponsor is Pharmazz, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Sovateltide works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Sovateltide works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Sovateltide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.